EBAMed secures EUR 1.6M, concluding Series A Round at EUR 16M
27.01.2025
Geneva-based Medtech startup EBAMed has successfully closed its Series A financing round, raising an additional EUR 1.6 million. Specializing in a guidance system for non-invasive heart arrhythmia treatment using Proton Therapy, EBAMed had initially secured EUR 14.35 million in June 2023. With this latest investment, the company’s total Series A funding now stands at EUR 16 million, reinforcing its focus on innovative solutions for cardiac care.
 EBAMed's team
|
 |
EBAMed has secured additional funding from CDP Venture Capital under the PNRR (Piano Nazionale di Ripresa e Resilienza) and the Next Generation EU initiative. This marks the startup's achievement of the EUR 16 million maximum investment outlined in its Series A agreement, led by CEO Marina Izzo.
In June 2023, EBAMed raised EUR 14.35 million in Series A funding to advance its CardioKit system through First-in-Human trials. Panakès Partners led the round, with support from the EIC Fund, Swiss EFI Lake Geneva Ventures, LIFTT Venture Capital Italia, OCCIDENT, and existing backers like Mayo Clinic.
Heart arrhythmias impact 50 million people globally, with numbers projected to rise as populations age. EBAMed’s CardioKit enables non-invasive treatment of ventricular tachycardias (VTs) using proton therapy. The system enhances precision by automatically adapting radiation delivery to cardiac motion, offering an alternative to drugs and catheter-based ablation while minimizing radiation exposure to healthy heart tissue.
EBAMed participated in Venture Leaders Life Sciences 2018, won Venture Kick Stage 3 in 2018, and was ranked in the TOP 100 Swiss Startup Award in 2019, 2022, and 2023.
EBAMed's team
In June 2023, EBAMed raised EUR 14.35 million in Series A funding to advance its CardioKit system through First-in-Human trials. Panakès Partners led the round, with support from the EIC Fund, Swiss EFI Lake Geneva Ventures, LIFTT Venture Capital Italia, OCCIDENT, and existing backers like Mayo Clinic.
Heart arrhythmias impact 50 million people globally, with numbers projected to rise as populations age. EBAMed’s CardioKit enables non-invasive treatment of ventricular tachycardias (VTs) using proton therapy. The system enhances precision by automatically adapting radiation delivery to cardiac motion, offering an alternative to drugs and catheter-based ablation while minimizing radiation exposure to healthy heart tissue.
EBAMed participated in Venture Leaders Life Sciences 2018, won Venture Kick Stage 3 in 2018, and was ranked in the TOP 100 Swiss Startup Award in 2019, 2022, and 2023.
EBAMed's team